SecurityROSE / Rosehill Resources Inc.
Institutional Buyers14
Related ROSEU / Rosehill Resources
ROSEW / Rosehill Resources, Warrants

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in ROSE / Rosehill Resources Inc. include .

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Prev Shares Shares Change
Prev Value
Current Value (x$1000) Change
2018‑05‑14 13F-HR K2 PRINCIPAL FUND, L.P. 457,115 460,615 0.77 3,234 1,901 -41.22
2018‑05‑15 13F-HR MILLENNIUM MANAGEMENT LLC 11,525 18,600 61.39 91 109 19.78
2018‑05‑15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,490 2,367 58.86 12 14 16.67
2018‑05‑15 13F-HR BARCLAYS PLC 400 523 30.75 3 3 0.00
2018‑05‑15 13F-HR STATE STREET CORP 16,646 18,346 10.21 130 108 -16.92
2018‑05‑07 13F-HR QUANTUM CAPITAL MANAGEMENT 93,209 214,442 130.07 733 1,259 71.76
2018‑05‑02 13F-HR WELLS FARGO & COMPANY/MN 147,808 155,546 5.24 1,162 913 -21.43
2018‑04‑16 13F-HR Malaga Cove Capital, LLC 0 11,300 0 66
2018‑05‑11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 114 162 42.11 0 0
2018‑05‑14 13F-HR MORGAN STANLEY 25,322 26,771 5.72 199 157 -21.11
2018‑05‑10 13F-HR Stratos Wealth Partners, LTD. 5,900 9,900 67.80 46 58 26.09
2018‑05‑09 13F-HR BlackRock Inc. 131,055 135,759 3.59 1,031 796 -22.79
2018‑05‑15 13F-HR Tower Research Capital LLC (TRC) 0 2,503 0 15

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 777385105